FIELD: medicine.
SUBSTANCE: group of inventions concerns application an anti-PVRIG antibody (a human poliovirus-related protein-containing protein containing an immunoglobulin domain), activating T-cells and/or NK cells, for treating cancer, characterized by the expression of PVRIG and/or PVRL2. Group of inventions also relates to a method of activating T-cells of a patient suffering from cancer, characterized by expression of PVRIG and/or PVRL2, comprising administering to patient PVRIG antibodies; a composition of expression vectors for expressing the anti-PVRIG antibody; a host cell for expressing the anti-PVRIG antibody, containing said composition of expression vectors.
EFFECT: group of inventions provides treating cancer characterized by expression of PVRIG and/or PVRL2.
58 cl, 103 dwg, 5 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
